Patents Represented by Attorney Laura Donnelly
  • Patent number: 8290581
    Abstract: The present invention is directed to an apparatus that includes a microcurrent delivery device portion and at least one independent sensory cue delivery means. The independent sensory cue delivery means can provide an independent sensory cue selected from the group consisting of vibration, heat, cool, skin irritation, tingling, fragrance or auditory.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: October 16, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Leo B. Kriksunov, Aliya Z. Omer, Edward Roche, Joshua Ghaim, Naomi Furgiuele
  • Patent number: 8211465
    Abstract: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: July 3, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Frank Bunick, James Schwing
  • Patent number: 8183290
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. In particular a 2:1 complex of naproxen sodium to propylene glycol is disclosed which is a crystalline solid. The complex is prepared by crystallization of a mixture of naproxen sodium and propylene glycol from diethyl ether. It is identifiable by its X-ray powder diffraction pattern described herein.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: May 22, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
  • Patent number: 8137694
    Abstract: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: March 20, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Frank Bunick, James Schwing
  • Patent number: 8114328
    Abstract: Systems, methods and apparatuses for manufacturing dosage forms, and to dosage forms made using such systems, methods and apparatuses are provided. Novel compression, thermal cycle molding, and thermal setting molding modules are disclosed. One or more of such modules may be linked, preferably via novel transfer device, into an overall system for making dosage forms.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: February 14, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Harry S. Sowden, Bernard F. Plantz, Shun Por Li
  • Patent number: 8067029
    Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: November 29, 2011
    Assignee: McNeil-PPC, Inc.
    Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Atul Ayer, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
  • Patent number: 8057820
    Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated granule comprising an intimate mixture of an aspirin active ingredient and at least one binder capable of preferentially absorbing ambient moisture.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: November 15, 2011
    Assignee: McNeil-PPC, Inc.
    Inventors: Manoj N. Shah, James S. Beahm, Robert Shen
  • Patent number: 7972624
    Abstract: In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: July 5, 2011
    Inventors: Shun-Por Li, Harry S. Sowden, David Wynn, Der-Yang Lee, Martin Thomas
  • Patent number: 7968120
    Abstract: In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated.
    Type: Grant
    Filed: September 28, 2002
    Date of Patent: June 28, 2011
    Assignee: McNeil-PPC, Inc.
    Inventors: Shun-Por Li, Harry S Sowden, David Wynn, Der-Yang Lee, Martin Thomas
  • Patent number: 7838026
    Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and at least one carrageenan is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, to provide burst release of active ingredient contained therein.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: November 23, 2010
    Assignee: McNeil-PPC, Inc.
    Inventors: Shun-Por Li, Der-Yang Lee, Frank J. Bunick, Jen Chi Chen, Harry S. Sowden
  • Patent number: 7734371
    Abstract: The present invention is directed to a vending system or automated store and method of practice that has a means for inputting data, e.g., data input device, means for analyzing the data, e.g., microprocessor, and an output based on the analysis that includes information, product, or both. The invention is particularly suited for the delivery of healthcare and/or personal care products. The system provides a prospective consumer with information about products and their use, and preferably is capable of accessing qualified savings accounts for purposes of completing a transaction.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: June 8, 2010
    Assignee: McNeil-PPC, Inc.
    Inventor: Leo J Garneau, III
  • Patent number: 7635490
    Abstract: The invention provides a dosage form comprising at least one active ingredient, and first core and second cores surrounded by and separated by a shell. The dosage form provides a delay of at least one hour between the initial release of active ingredient contained in said first core and the initial release of active ingredient contained in said second core after contacting of the dosage form with a liquid medium.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: December 22, 2009
    Assignee: McNeil-PPC, Inc.
    Inventors: David Wynn, Gerard P. McNally, Harry S. Sowden
  • Patent number: 7615533
    Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: November 10, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Edward J. Yurkow, Brian R. MacDonald, Jeffery K. Weis
  • Patent number: 7579356
    Abstract: The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: August 25, 2009
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Niranjan B. Pandey, Mark T. Powell
  • Patent number: 7575888
    Abstract: It is now discovered that human chymase cleaves human SLPI at a specific site and that this cleavage can be used as an indicator of chymase activity. The present invention provides methods of diagnosing a chymase-associated disease or evaluating the efficiency of a treatment of a chymase-associated disease in a human subject by measuring SLPI processing, as well as other related methods and compositions.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: August 18, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Stanley Belkowski, Michael R. D'Andrea
  • Patent number: 7576056
    Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: August 18, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Brian R. MacDonald, Jeffery Kenneth Weis, Edward John Yurkow
  • Patent number: 7575882
    Abstract: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: August 18, 2009
    Assignee: Janssen Pharmaceutica N. V.
    Inventors: Ning Qin, Yi Liu, Christopher M. Flores, Tasha Hutchinson, Michael P. Neeper
  • Patent number: 7563922
    Abstract: Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a N-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof are provided, said processes comprise: a) reacting 4-(2-cyanoethenyl)-2,6-dimethylbenzenamine with an intermediate of formula (III) ?in the presence of a suitable solvent; b) reacting an intermediate of formula (IV) ?with acrylonitrile in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent; c) dehydrating the corresponding amide of the compound of formula (I).
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: July 21, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Didier Philippe Robert Schils, Joannes Josephus Maria Willems, Bart Petrus Anna Maria Jozef Medaer, Elisabeth Therese Jeanne Pasquier, Paul Adriaan Jan Janssen, Jan Heeres, Ruben Gerardus George Leenders, Jérôme Emile Georges Guillemont
  • Patent number: 7541367
    Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: June 2, 2009
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: George Chiu, Peter J. Connolly, Stuart Emanuel, Shenlin Huang, Shengjian Li, Ronghui Lin, Yanhua Lu, Steven A. Middleton
  • Patent number: 7541476
    Abstract: The present invention provides a radiolabeled astemizole of formula (III) and a process for preparing the radiolabeled astemizole of formula III.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: June 2, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Godelieve Irma Christine Maria Heylen, Cornelus Gerardus Maria Janssen, Jurzak Mirek, Henricus Petrus Martinus Maria Van Assouw